“For TB treatment to be effective, consider the male perspective”

This article was originally published on Health-E News on 14 April 2021, by Ndivhuwo Mukwevho.   In South Africa, Tuberculosis (TB) affects more men than women. The Desmond Tutu Health Foundation has called for the consideration of men’s voices when designing treatment and prevention programmes. The current ‘one-size-fits all approach’ is not working to adequately…

Details

2021 Adolescent Youth Health Policy Online Short Course

We are excited to announce we are running the 2020 Adolescent Youth Health Policy Online Short Course The course will start on 01 May 2021 Application deadline: 23 April 2021 Developed to support staff or governmental & non-governmental organizations working at national, provincial & district levels, in the implementation of the national policies targeting young…

Details

In Memory of Dr. Charles Boucher

The DTHF would like to express our regret and sadness at the news of the passing of Dr. Charles Boucher, an esteemed virologist, and pioneer in the early study of HIV drug resistance. Within the scientific community, Dr. Boucher was unparalleled in his commitment to moving HIV research and medicine forward and paved the way…

Details

DTHF WELCOMES EARLY DATA FROM ENSEMBLE TRIAL, SHOWING SAFETY & EFFICACY FOR SINGLE -SHOT JANSSEN COVID-19 VACCINE CANDIDATE

Johnson & Johnson today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating its investigational single-dose COVID-19 vaccine met all primary and key secondary endpoints. The topline safety and efficacy data are based on 44,325 44 participants accruing 468 symptomatic cases of COVID-19. The Desmond Tutu Health Foundation is a…

Details

Efficacy Results announced: global first Antibody Mediated Prevention (AMP) trials

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains.   The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains that were sensitive to the bnAb. This was assessed by a laboratory test that measures a virus’…

Details

DTHF Mourns the loss of Professor David Katzenstein

The Desmond Tutu Health Foundation was very sad to hear about the passing of our long-time friend and collaborator, Professor David Katzenstein, today of Covid-19 complications. David was a passionate and respected Professor of Medicine at Stanford University, specializing in the treatment and evaluation of HIV infection. Since the 80s when he and Dr. Wood…

Details